Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease

NCT02907749 is registered in ClinicalTrials.gov with Changqing Yang as lead sponsor.

NCT NCT02907749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02907749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease
Lead sponsor
Changqing Yang
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2018
Completion date
July 31, 2020
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, portal hypertension